linjc16/ctgov huggingface dataset:
Vaginal Profile in IVF/ICSI and Impact on Clincal Outcome

Study Overview
=================
Brief Summary
-----------------
Vaginal flora is closely related to female reproductive health. Previous studies have suggested that the composition of the vaginal flora is related to the pregnancy outcomes, and abnormalities in the vaginal flora lead to a decrease in the success rate of IVF. During the IVF treatment, the hormone level changes far exceed the physiological level. What changes will happen to the vaginal flora? Does IVF treatment itself affect the vaginal flora and affect outcomes? This study used prospective cohort study to show the changes in vaginal flora during conventional IVF treatment, providing more evidence for revealing the relationship between vaginal flora and infertility treatment outcomes.

Official Title
-----------------
The Impact of Vaginal Profile During Ovarian Stimulation on the IVF/ICSI Outcome: a Prospective Observational Study

Conditions
-----------------
Vaginal Flora Imbalance

Intervention / Treatment
-----------------
* Procedure: IVF/ICSI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20-40 years old BMI<30kg/m2 First IVF/ICSI cycle (GnRH agonist or antagonist protocol) no vaginitis after recruitment completion of oocyte retrieval Exclusion Criteria history of RSA history of endometriosis Immune diseases such as SLE, etc., and the use of immunosuppressive agents, glucocorticoids, etc. obvious hydrosalpinx(>2cm in diameter by ultrasound)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: IVF/ICSI|ovarian stimulation ，vaginal disinfection of flushing|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical pregnancy rate | no. of clinical pregnancy / total number of embryo transfer cycles | 12.2019-03.2020 |
A Gray Zone Approach of Rotational Thromboelastometry for Predicting Postoperative Bleeding in Cardiac Surgical Patients

Study Overview
=================
Brief Summary
-----------------
Rotational thromboelastometry (ROTEM) is reliable point of care management of coagulation disorder undergoing surgery. Recently, there are some reports about prediction of perioperative bleeding using ROTEM. But, the effectiveness of ROTEM for predict bleeding and improve outcomes is still debate. In this retrospective study, the investigators will compare immediate postoperative bleeding with ROTEM parameters using a Gray zone approach, and access the reliability of ROTEM for prediction of bleeding after cardiac surgery.

Official Title
-----------------
The Effectiveness Evaluation of Rotational Thromboelastometry(ROTEM) for Predicting Postoperative Bleeding in Cardiac Surgical Patients Using a Gray Zone Approach : A Preliminary Retrospective Study

Conditions
-----------------
Other Functional Disturbances Following Cardiac Surgery, Postoperative Hemorrhage, Coagulation Defect; Bleeding

Intervention / Treatment
-----------------
* Device: ROTEM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cardiac surgical patients using Cardiopulmonary bypass Exclusion Criteria: known coagulation disorder Using deep hypothermic circulatory arrest Using partial cardiopulmonary bypass

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ROTEM<br> | Device: ROTEM<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| early postoperative bleeding(chest tube drainage) | primary outcome is Chest tube drainage(blood volume) during 6hrs. | postoperative bleeding during 6hrs. |
Reusable Duodenoscope Culture Registry

Study Overview
=================
Brief Summary
-----------------
This project is being performed to examine the results of duodenoscope cultures following standard of care cleaning and reprocessing.

Detailed Description
-----------------
This project is being performed to examine the results of duodenoscope cultures following standard of care cleaning and reprocessing. This information will allow us to elucidate the number of endoscopic procedures that can be performed using a single duodenoscope until microorganisms are cultured from duodenoscopes after standard of care cleaning and reprocessing. This will in turn allow us to improve the delivery of healthcare to patients undergoing endoscopic procedures.

Official Title
-----------------
Registry of Culture Results From Reusable Duodenoscopes

Conditions
-----------------
Endoscopy

Intervention / Treatment
-----------------
* Other: Duodenoscope Culture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or greater Any patient undergoing endoscopic retrograde cholangiopancreatography procedure using a reusable duodenoscope Exclusion Criteria: Less than 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Duodenoscope Culture|Culture of reusable duodenoscopes following each use.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microorganism Growth | The aim of this registry is to identify the number of endoscopic procedures that can be performed using reusable duodenoscopes before microorganisms are grown from duodenoscope cultures following standard of care cleaning and reprocessing. This will enable us to identify the maximum number of procedures that can be performed with a single duodenoscope before being sent to the manufacturer to be refurbished. | 6 months |
Existential Issues in Elderly People With Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose is to describe, interpret and provide a detailed understanding of what it means to be elderly people with cancer who receive treatment in specialized health care. Focus is especially put on the content and expression of existential issues and the importance of spirituality for the patient´s life story and medical story.

Detailed Description
-----------------
Existential and spiritual issues in elderly people with cancer are scarcely investigated with respect to the content and importance of these aspects to this patient group in terms of living with their disease and benefit from specialist health treatment and care. The present study is an independent doctoral study that also has an initial function for an intended multidisciplinary research project with the working title Aged people with cancer.

Official Title
-----------------
Existential Issues in Elderly People With Cancer in an Early Palliative Phase- a Phenomenological Hermeneutic Approach

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with cancer from the age 70 and older receiving palliative treatment in specialized health care Exclusion Criteria: Terminal patients Patients considered as too sick for the interview session Patients with lack of consent

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cancer in elderly people<br>other | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neoplasms, existentialism, existential concerns, Meaning making, early palliative phase, elderly
The Efficacy of Intensive Nutritional Supplement in Patient With Stroke

Study Overview
=================
Brief Summary
-----------------
The aim of this prospective randomized controlled study is to demonstrate the efficacy of Intensive Nutritional Supplement in Patient with Stroke.

Detailed Description
-----------------
Elderly patients, including those who have had a stroke, are more at risk of undernutrition than other groups because of reduced nutritional reserves, prolonged hospital stay and increased demands of repeated ill-health. Stroke may compound these problems because of physical and mental incapacity, problems with perception and communication, and swallowing disorders. The full extent of undernutrition and its independent contribution to stroke outcome is not presently known. It is also not known whether it can be corrected, and whether doing so would improve the outcome. The aim of this study is therefore to describe the efficacy of Intensive Nutritional Supplement in Patient with Stroke.

Official Title
-----------------
The Efficacy of Intensive Nutritional Supplement in Patient With Stroke: a Prospective Randomized Controlled Trial

Conditions
-----------------
Stroke, Malnutrition

Intervention / Treatment
-----------------
* Dietary Supplement: high protein supplement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1 st onset stroke patient MRI confirms his/her stroke more than 2.5% weight los within 2 weeks initial serum albumin < 35 g/l BMI < 18.5 more than MMSE 10 medically stable Exclusion Criteria: recurrent stroke patient malabsorption patient terminal cancer
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: high protein supplement<br>high protein supplement given | Dietary Supplement: high protein supplement<br>* Dietary Supplement: high protein supplement<br>* Other names: Intensive Nutritional Supplement group;|
| No Intervention: Control<br>no intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Modified Barthel Index (MBI) Score at 6 Months | Scale range: 0-100 (higher values represent a better outcome) | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chemical Laboratory Findings |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
malnutrition, high protein, stroke
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Study Overview
=================
Brief Summary
-----------------
This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.

Official Title
-----------------
Efficacy, Safety and PK of CD7 CAR-T in Patients With Relapsed or Refractory CD7+ Hematological Malignancies

Conditions
-----------------
Hematological Malignancies

Intervention / Treatment
-----------------
* Drug: Anti-CD7 CAR-T


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed CD7 positive relapsed/refractory hematological malignancies. Echocardiography shows left ventricular ejection fraction (LVEF) ≥ 50%; There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%; The estimated survival time is more than 3 months; Eastern cooperative oncology group (ECOG) performance status of 0 to 2 The patients or their legal guardians voluntarily participated in the trial and signed the informed consent. Exclusion Criteria: Patients with history of epilepsy or other central nervous system diseases; Patients with prolonged QT or severe heart disease; Pregnant or lactating women Patients with uncontrolled active infection. Positive for any of the following etiological tests: HIV, HBV, HCV Any other conditions that researcher think it is inappropriate for the subject to anticipate the trial

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: anti-CD7 UCAR-T cells<br> | Drug: Anti-CD7 CAR-T<br>* Universal CAR-T cells targeting CD7<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Response Rate(ORR) | Number of patients who achieved response after treatment of CD7 CAR-T cell. | 1 Year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of overall response (DOR) | Duration of overall response will be assessed from the CAR-T cell infusion to progression, death or last follow-up. | 1 Year | 
| Overall survival(OS) | OS will be assessed from the CAR-T cell infusion to death or last follow-up. | 1 Year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
T-ALL/LBL, AML
Serrated Polyp Detection Rate Between Carbon Dioxide and Air Insufflation

Study Overview
=================
Brief Summary
-----------------
Sessile serrated adenomas are characterized by their flat shape and the presence of a yellow mucus cap overlying the lesion. These morphological features may account for their diagnostic difficulty during colonoscopy. Missed proximal sessile serrated adenomas are regarded as an important cause for interval cancers in the right colon and emphasize the importance of developing quality measures intended to enhance their detection. There is only one single-center retrospective cohort study on the impact of carbon dioxide insufflation on the detection of serrated polyps during colonoscopy. The investigators designed a randomized, controlled trial to compare the effect of carbon dioxide insufflation vs. room air insufflation on serrated polyp detection rate.

Official Title
-----------------
Comparison of Serrated Polyp Detection Rate Between Carbon Dioxide and Air Insufflation During Colonoscopy: a Randomized Controlled Multicenter Trial

Conditions
-----------------
Serrated Polyp

Intervention / Treatment
-----------------
* Procedure: Carbon dioxide insufflation colonoscopy
* Procedure: Air insufflation colonoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Patients 45-75-years-old who underwent a colonoscopy - Exclusion Criteria:polyposis syndrome, Inflammatory bowel disease, previous colorectal operation -

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Carbon dioxide insufflation colonoscopy<br>Carbon dioxide insufflation colonoscopy | Procedure: Carbon dioxide insufflation colonoscopy<br>* Carbon dioxide insufflation colonoscopy<br>|
| Active Comparator: Air insufflation colonoscopy<br>Room air insufflation colonoscopy | Procedure: Air insufflation colonoscopy<br>* Room air insufflation colonoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serrated polyp detection rate |  | 7 days |
Cerebral Microembolism in Cardiology

Study Overview
=================
Brief Summary
-----------------
During different interventional cardiology procedures we aim to identify cerebral microemboli load. Further we aim to differentiate the quality and the quantity of cerebral microemboli.We will measure cerebral microemboli in different interventional phases, e.g. during valve deployment, rapid pacing, post-implantation.

Official Title
-----------------
Cerebral Microembolism in Interventional Cardiology Procedures

Conditions
-----------------
Cerebral Embolism

Intervention / Treatment
-----------------
* Device: Transcranial Doppler (TCD) ultrasound measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Interventional cardiology procedure (TAVI, MitraClip, TricuspidalClip) Exclusion Criteria: Allergy to ultrasound gel or materials contained in the TCD probe Missing temporal bone window

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TAVI patients<br>Patients undergoing transfemoral TAVI | Device: Transcranial Doppler (TCD) ultrasound measurement<br>* Non-invasive measurement of cerebral embolic load and blood flow using TCD<br>|
| MitraClip patients<br>Patients undergoing MitraClip implantation | Device: Transcranial Doppler (TCD) ultrasound measurement<br>* Non-invasive measurement of cerebral embolic load and blood flow using TCD<br>|
| TricuspidalClip<br>Patients undergoing TricuspidalClip implantation | Device: Transcranial Doppler (TCD) ultrasound measurement<br>* Non-invasive measurement of cerebral embolic load and blood flow using TCD<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of cerebral microemboli (solid vs. gaseous) | The quality of cerebral microemboli is measured by Doppler ultrasonography which automatically detects and analyses the Doppler signal coming from the middle cerebral artery. According to the strength of signal reflection, the signal will be qualified as solid or gaseous. | intraoperative phase, expected to be approx. 4 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantity of cerebral microemboli load | The quantity of cerebral microemboli is measured by Doppler ultrasonography which automatically register the counts of solid and gaseous emboli. | intraoperative phase, expected to be approx. 4 hours | 
| Cerebral hemispheric differences (left vs. right) |  | intraoperative phase, expected to be approx. 4 hours |
Flurbiprofen Axetil for Uterine Contraction Pain

Study Overview
=================
Brief Summary
-----------------
Uterine contraction pain is a common problem after abortion. Optimal analgesic for such suffering is still needed to be guaranteed. Flurbiprofen Axetil is a target-distributable non-steroidal anti-inflammatory drug (NSAID) functioning via block the synthesis of prostaglandin E (PGE). The investigators hypothesized that Flurbiprofen Axetil could suppress the uterine contraction pain after abortion effectively.

Official Title
-----------------
Phase IV Study of Flurbiprofen Axetil for Uterine Contraction Pain After Abortion

Conditions
-----------------
Postoperative Pain

Intervention / Treatment
-----------------
* Drug: Saline
* Drug: Flurbiprofen Axetil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA status I-II Performing abortion operation (medical- or drug-induced Requiring painless abortion Exclusion Criteria: < 19yrs, and >= 45yrs History of central active drugs administration Drug abuse Hypertension Diabetes Any other chronic diseases Allergy to the study drugs Habit of over-volume alcohol drinking Records of history of centrally active drug use and psychiatry Any organic disorders

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>Saline 5 ml injection 10 min prior to propofol administration. | Drug: Saline<br>* Saline 5 ml injection 10 min prior to propofol administration.<br>* Other names: Ringer's solution;|
| Experimental: 2<br>Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration. | Drug: Flurbiprofen Axetil<br>* Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.<br>* Other names: KaiFen;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS pain scorings |  | At the end of the operation, 0,5,15,30,60min after operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anesthetic consumptions |  | At the end of the operation | 
| Overall VAS satisfaction scorings with analgesia |  | At the end of the study | 
| Side effects |  | During the whole period of the study | 
| Volume of bleeding |  | At the end of the study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NSAIDs, Postoperative pain, Analgesia, Abortion